RT Journal Article
T1 Flavonoids and the Risk of Gastric Cancer: An Exploratory Case-Control Study in the MCC-Spain Study
A1 Vitelli Storelli, Facundo
A1 Capelo Álvarez, Rocío
A1 Martín, Vicente
AB Several epidemiological studies have investigated the association between the dietaryflavonoid intake and gastric cancer (GC) risk; however, the results remain inconclusive. Investigatingthe relationship between the different classes of flavonoids and the histological types and origin ofGC can be of interest to the research community. We used data from a population-based multi-casecontrol study (MCC-Spain) obtained from 12 different regions of Spain. 2700 controls and 329 GCcases were included in this study. Odds ratios (ORs) were calculated using the mixed effects logisticregression considering quartiles of flavonoid intakes and log2. Flavonoid intake was associatedwith a lower GC risk (ORlog2 = 0.76; 95% CI = 0.65–0.89; ORq4vsq1 = 0.60; 95%CI = 0.40–0.89;ptrend = 0.007). Inverse and statistically significant associations were observed with anthocyanidins,chalcones, dihydroflavonols and flavan-3-ols. The isoflavanoid intake was positively associated withhigher cancer risk, but without reaching a statistical significance. In general, no differences wereobserved in the GC risk according to the location and histological type. The flavonoid intake seemsto be a protective factor against GC within the MCC-study. This effect may vary depending on theflavonoid class but not by the histological type and location of the tumor. Broader studies with largersample size and greater geographical variability are necessary.
PB MDPI
SN 2072-6643
YR 2019
FD 2019
LK http://hdl.handle.net/10272/16226
UL http://hdl.handle.net/10272/16226
LA eng
NO Vitelli Storelli, F., Molina, A. J., Zamora-Ros, R., Fernández-Villa, T., Roussou, V., Romaguera, D., Capelo Álvarez, R, Martín, V. (2019). Flavonoids and the Risk of Gastric Cancer: An Exploratory Case-Control Study in the MCC-Spain Study. Nutrients, 11(5), 967. https://doi.org/10.3390/nu11050967
NO The study was partially funded by the “Accion Transversal del Cancer”, approved on the SpanishMinistry Council on 11 October 2007, by the Instituto de Salud Carlos III-FEDER (PI08/1770, PI08/0533,PI08/1359, PS09/00773-Cantabria, PS09/01286-León, PS09/01903-Valencia, PS09/02078-Huelva, PS09/01662-Granada,PI11/01403, PI11/01889-FEDER, PI11/00226, PI11/01810, PI11/02213, PI12/00488, PI12/00265, PI12/01270, PI12/00715,PI12/00150, PI14/01219, PI14/0613, PI15/00069, PI15/00914, PI15/01032, PI17CIII/00034), by the Fundación Marqués de Valdecilla (API 10/09), by the ICGC International Cancer Genome Consortium CLL (The ICGC CLL-GenomeProject is funded by Spanish Ministerio de Economía y Competitividad (MINECO) through the Instituto deSalud Carlos III (ISCIII) and Red Temática de Investigación del Cáncer (RTICC) del ISCIII (RD12/0036/0036)), bythe Junta de Castilla y León (LE22A10-2), by the Consejería de Salud of the Junta de Andalucía (PI-0571-2009,PI-0306-2011, salud201200057018tra), by the Conselleria de Sanitat of the Generalitat Valenciana (AP_061/10),by the Recercaixa (2010ACUP 00310), by the Regional Government of the Basque Country, by the Consejería deSanidad de la Región de Murcia, by the European Commission grants FOOD-CT-2006-036224-HIWATE, by theSpanish Association Against Cancer (AECC) Scientific Foundation – grant GCTRA18022MORE, by the CatalanGovernment- Agency for Management of University and Research Grants (AGAUR) grants 2017SGR723 and2014SGR850, by the Fundación Caja de Ahorros de Asturias and by the University of Oviedo. ISGlobal is amember of the CERCA Programme, Generalitat de Catalunya.
DS Repositorio Institucional de la Universidad de Huelva
RD 1 jun 2026